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Testicular cancer is the most common cancer in men between the
ages of 15 and 35. Before the development of platinum-based
chemotherapy in the 1970s and 1980s (Einhorn and Donohue,
1977; Einhorn and Williams, 1980), metastatic germ cell tumours
of the testis were almost universally fatal. Now that the majority of
these cases are cured, consideration of the toxicity of treatment
takes on a greater importance. 
Cisplatin, an essential component of chemotherapy for
metastatic germ cell tumours, is a toxic drug. Initially, the domi-
nant toxicities were nephrotoxicity and vomiting, but these are
now usually well controlled with saline diuresis (Hardaker et al,
1974) and potent antiemetics. Neurotoxicity is also common
(Kedar et al, 1978) and can be a significant cause of morbidity.
Though usually mild it can occasionally be dose limiting. More
commonly however the symptoms of neurotoxicity appear shortly
after the end of treatment and persist for several months. There are
few data on this in patients with germ cell tumour and none on the
time course of the symptoms. It can therefore be difficult to advise
patients on the chances of developing neurotoxicity and on its
prognosis once it has developed. 
Neurotoxicity is usually assessed in patients receiving
chemotherapy by enquiring about symptoms and by physical
examination. The most sensitive indicator of cisplatin-induced
peripheral neuropathy is the vibration sensation threshold, which
may be elevated even in asymptomatic patients (Ashraf et al,
1983). Nerve conduction studies, looking at both conduction
velocities and action potentials, are also commonly performed
(e.g. Cavaletti et al, 1992). We therefore performed a prospective
longitudinal study on men undergoing chemotherapy for
metastatic germ cell tumour to determine the incidence, time
course and reversibility of neurotoxicity. 
METHODS 
Patients 
29 patients with testicular germ cell tumour requiring cytotoxic
chemotherapy (median age 30 years, range 14–50 years) were
studied. Most patients received 3 or 4 cycles of BEP (bleomycin,
etoposide and cisplatin), each cycle containing cisplatin 
100 mg m–2 (Einhorn et al, 1987). Patients with seminoma received
chemotherapy with less bleomycin. 2 patients were treated with
BOP-VIP (bleomycin, vincristine and cisplatin alternating with
etoposide, ifosfamide and cisplatin) (Kaye et al, 1998), and 2
received lower doses of cisplatin than intended (not because of
neurotoxicity). One patient received high-dose chemotherapy after
initial treatment. 
Clinical assessment 
Careful enquiry was made concerning the presence of numbness
and paraesthesiae during the follow-up period, initially at 6-week
intervals extending to 2 monthly after 6 months. 27 sets of case
notes were examined for these. The median follow-up was 4 years
(range 2–8 years). 
Neurophysiology 
Vibration sensation threshold was determined using the
Biothesiometer (Bio-Medical, Ohio). A cylindrical stylus, 13 mm
in diameter, vibrating at 100 Hz, was allowed to rest on the
patient’s great toe. The amplitude of vibration was varied by the
operator, and the patient was asked to report the appearance or
disappearance of the vibration (Nielsen, 1972). The readings were
read off the dial and expressed in ‘biothesiometer units’. This tech-
nique has good reproducibility, suitable for serial measurements in
clinical trials (Le Quesne and Fowler, 1987). Biothesiometry was
performed at the beginning and at the end of chemotherapy, and
at intervals subsequently. By 12 months following the end of
chemotherapy, 29 patients had undergone 81 tests. The sural nerve
Cisplatin neurotoxicity in the treatment of metastatic
germ cell tumour: time course and prognosis 
M von Schlippe1, CJ Fowler2 and SJ Harland1,2
1Department of Oncology, University College, London, WIN 8AA; 2Institute of Urology and Nephrology, University College, London, WIN 8AA, UK 
Summary In order to ascertain the incidence and prognosis of cisplatin-induced neurotoxicity in testis cancer patients undergoing combination
chemotherapy, 29 patients with metastatic disease were studied prospectively. Assessments included enquiry into neurological symptoms,
measurement of sural nerve sensory action potential and conduction velocity, and vibration threshold in the left big toe. At the end of chemotherapy
(3 to 4 cycles) only 3 out of 26 (11%) patients had paraesthesiae, but 3 months later the proportion rose to 65%. Resolution occurred in the majority
over the ensuing 12 months so that only 17% had persistent symptoms. None of the 11 patients treated with 3 cycles of chemotherapy had
persisting symptoms. Vibration thresholds showed a significant deterioration during chemotherapy (P = 0.032), further deterioration in the 3
months following chemotherapy (P = 0.009) and significant improvement between 3 and 12 months after chemotherapy (P = 0.038). Sural nerve
sensory action potentials and conduction velocities were unhelpful. ©2001 Cancer Research Campaign http://www.bjcancer.com 
823
Received 28 February 2001 
Revised 21 June 2001 
Accepted 5 July 2001 
Correspondence to: SJ Harland 
British Journal of Cancer (2001) 85(6), 823–826
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2006, available online at http://www.idealibrary.com on  http://www.bjcancer.com
BJOC 01-2006 823-826  10/9/01  2:04 pm  Page 823sensory action potential and conduction velocity were measured
using surface electrodes (di Benedetto, 1970). Test results were
grouped according to the nearest 3 month time period. Statistical
evaluation of the mean changes in value from baseline was
performed using a paired t-test. 
RESULTS 
Data on symptoms were available on 26 of the 29 patients studied
(Table 1, Figure 1). Review of patient records showed that 3
patients had paraesthesiae at the end of treatment. A further 14
became symptomatic later (3 at 1 month, 1 at 2 months, and the
remaining 10 at 3 months). All neurotoxicity was WHO Grade I
(mild paraesthesiae) apart from 2 cases which were Grade II
(severe paraesthesiae). Resolution of symptoms was documented a
mean of 4 months later (range 2 weeks to 1 year after the onset of
symptoms) in 12 patients. 
5 patients had persistent symptoms. 2 had received vincristine
as part of the BOP-VIP regimen, and 1 had received high-dose
chemotherapy with carboplatin, etoposide and cyclophosphamide
on relapse. 2 others had received a cumulative dose of cisplatin of
400 and 600 mg m–2. 
The time course of reported symptoms correlated well with
changes in the vibration threshold (Figure 2). By the end of treat-
ment, a modest rise in vibration threshold could be seen. The
vibration threshold peaked 3 months later, and then began to
resolve, with a substantial improvement at 6 months, and almost
complete recovery at 18 months. Statistical analysis of the paired
data out to 12 months after the completion of chemotherapy (Table
2) confirmed that vibration threshold was higher than before the
start of chemotherapy. The vibration threshold at 3 and 6 months
was significantly worse than immediately after the end of
chemotherapy. By 12 months, however, significant improvement
in the vibration threshold had occurred as compared to the vibra-
tion threshold at 3 months (Table 2). 
There was an apparent relationship between the severity of
neurotoxicity and the total cisplatin dose (Figure 3). However,
small numbers prevented statistical confirmation of this observa-
tion. 
We also examined the changes in sural nerve sensory action
potential (Figure 4A) and conduction velocity (Figure 4B). No
significant deviations from baseline could be detected in either
case. 
DISCUSSION 
The neurotoxicity of cisplatin poses a significant clinical problem.
Symptoms may be troublesome and persistent, and may even lead
to treatment with cisplatin being curtailed. Together with nephro-
toxicity, neurotoxicity also limits the scope for dose intensification
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Table 1 Occurrence and resolution of neurological symptoms according to
total cisplatin (CDDP) dose 
Symptoms 
Cumulative cisplatin 
None Resolved Persisted No data Total dose (mg m–2)
<300 0 2 0 1 3 
300 7 4 0 0 11 
400 and above 2 6 5* 2 15 
Total 9 12 5 3 29 
* 2 patients also received a total dose of vincristine 6 mg m–2. 
This table with only minor variations was previously published elsewhere
(von Schlippe et al, 1998). 
Figure 1 Proportion of patients with neurological symptoms after
completion of chemotherapy. *Patient received high dose chemotherapy at
12 months, therefore censored at 12 months 
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Figure 2 Variation of vibration threshold in the left big toe with cisplatin
chemotherapy. Symbols: o vibration threshold; — mean vibration threshold
(in Biothesiometer units) 
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Figure 3 Dependence of the variation in vibration threshold in the left big
toe on the cumulative dose of cisplatin. Symbols:   cisplatin <300 mg m–2; 
❐ cisplatin 300 mg m–2;   cisplatin >300 mg m–2
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BJOC 01-2006 823-826  10/9/01  2:04 pm  Page 824with cisplatin. In our study, we found that 5 out of 27 patients on
whom data were available remained symptomatic, an average of 5
years after the end of chemotherapy. Bokemeyer et al found that
17% of patients treated for testicular cancer who had been in
complete remission for at least 1 year still had symptoms of
neuropathy, 5% grading them as severe (Bokemeyer et al, 1996).
We also found that 12 of the 27 patients developed symptoms only
after the end of chemotherapy. Others have also found that the
symptoms of cisplatin neuropathy can progress after the end of
chemotherapy (Mollman et al, 1988; Grunberg et al, 1989), with
variable and unpredictable degrees of recovery. 
Because patients with metastatic germ cell tumour tend to
receive only 3 or 4 cycles of chemotherapy, they offer an opportu-
nity to study the development of cisplatin-induced neuropathy
even after chemotherapy has ended. We were able to correlate the
development of symptomatic neuropathy with a deterioration in
biothesiometry, and to follow their concurrent recovery. The
Biothesiometer, introduced into clinical practice in the 1950s
(Steiness, 1957a, 1957b), has been found to be as reliable as other
instruments in the assessment of vibration sensation (Le Quesne
and Fowler, 1987). Daugaard et al used the Biothesiometer in 8
patients undergoing BEP chemotherapy for germ cell tumours.
Abnormal biothesiometry was found in all the patients at the end
of 3 cycles of chemotherapy, and 4 patients had symptoms of
neuropathy (Daugaard et al, 1987). However, the biothesiometry
in these patients was not followed after the end of chemotherapy. 
In this study, we found that our patients’ symptoms followed the
changes in biothesiometry well. By contrast, neither the sural
nerve sensory action potential or sural nerve conduction velocity
correlated with either patients’ symptoms or their biothesiometry.
These methods have, however, been used frequently by other
investigators in the study of cisplatin neuropathy (e.g. Riggs et al,
1988; Cavaletti et al, 1994). They have shown decreases in the
sensory nerve action potential amplitude, although with wide vari-
ation. Motor parameters appear to be affected much less, and this
is borne out by the clinical observation that weakness due to
motoneurone damage is a late event that is rarely seen in response
to cisplatin chemotherapy. 
In this study, all patients receiving a cumulative dose of 
300 mg m–2 cisplatin had a full resolution of any neuropathy, and only
2 out of 11 patients receiving a cumulative dose of 400 mg m–2 had
persistent symptoms (Table 1). We have reported previously that
neurotoxicity appears to correlate with cumulative cisplatin dose
(von Schlippe et al, 1998). Certainly when 4 cycles of BEP
chemotherapy are compared with 3 in large numbers of patients,
the incidence of sensory symptoms is significantly higher (de Wit
et al, 2001). The role of dose intensity has been studied (Cavaletti
et al, 1992; Hilkens et al, 1995), but its significance is still 
unresolved. 
Our results illustrate the damaging effects of concurrent treat-
ment with other neurotoxic drugs, as 2 of the 3 patients treated
with vincristine developed persistent symptomatic neurotoxicity.
The advent of the taxanes, which have both a wide spectrum of
activity and significant neurotoxic side-effects, may lead to an
increase in neurotoxicity (Berger et al, 1997; Hilkens et al, 1997).
Neuroprotective agents are being investigated, including amifos-
tine (Foster-Nora and Siden, 1997; Planting et al, 1999) and the
ACTH analogue Org 2766 (Gerritsen van der Hoop et al, 1990).
As yet, none of these compounds is used routinely, and they can
have significant side-effects. Biothesiometry can provide a conve-
nient measure of their efficacy. 
Our results suggest that, if cisplatin is the only neurotoxic drug
in the regimen, full recovery of neurotoxicity is likely up to a
Cisplatin neurotoxicity 825
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Table 2 Vibration threshold of right big toe in relation to time of chemotherapy: paired data 
Time points Mean difference ± SE in biothesiometry units Paired observations P value 
Pre-chemo vs end-chemo 6.3 ± 2.6 16 0.032 
Pre-chemo vs 3 months post- 19.0 ± 3.7 11 < 0.001 
Pre-chemo vs 6 months post- 7.1 ± 1.7 9 0.003 
Pre-chemo vs 12 months post- 5.4 ± 1.8 16 0.009 
Pre-chemo vs 18 months post- 2.3 ± 1.2 3 NS 
End-chemo vs 3 months post- 11.8 ± 2.9 6 0.009 
End-chemo vs 6 months post- 5.2 ± 1.7 5 0.035 
3 months post- vs 12 months post- –8.0 ± 3.0 7 0.038 
− 6 − 3 0 3 6 9 1 21 51 821 24
Time from completion of cisplatin chemotherapy (months)
− 6 − 30 3 6 91 2 1 5 18
Time from completion of cisplatin chemotherapy (months)
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Figure 4 Sural nerve neurophysiology: variations in sensory action
potential (A) and nerve conduction velocity (B) after completion of
chemotherapy. Symbols: o sural nerve sensory action potential (A) or nerve
conduction velocity (B); — mean values
BJOC 01-2006 823-826  10/9/01  2:04 pm  Page 825cumulative dose of 400 mg m–2 of cisplatin without the use of
neuroprotective agents. This is likely to apply to the majority of
patients with metastatic germ cell tumour, most of whom will be
cured. 
In the event of disease relapse there should be a greater concern
about the development of long-term paraesthesiae. Whereas bio-
thesiometry will be able to provide an objective index of neuro-
toxicity it may not be of value in management since there is a
overriding need to give aggressive treatments despite non-lethal
toxicity and because the full extent of nerve damage is unlikely to
be detected until 2–4 months after the completion of treatment. 
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